Joana Carvalho, PhD, managing science editor —

Despite low muscle tone, young adults with Prader-Willi syndrome can do exercises involving resistance training and likely will benefit from greater muscle strength, a study suggests. The research, “Myokine levels after resistance exercise in young adults with Prader–Willi syndrome (PWS),” was published in the American Journal of Medical…

Early diagnosis and treatment of Prader-Willi syndrome may delay obesity and minimize the risk for associated complications, a study suggests. The study, “Early Diagnosis in Prader–Willi Syndrome Reduces Obesity and Associated Co-Morbidities,” was published in the journal Genes, and was led by researchers at the University…

The Data Safety Monitoring Board (DSMB) has recommended, for the second time, the continuation of Soleno Therapeutics’ Phase 3 DESTINY PWS clinical trial evaluating the effects of diazoxide choline controlled release (DCCR) for treating children and adults with Prader-Willi syndrome (PWS). DCCR is…

A group of clinicians has established a series of guidelines for the treatment of people with Prader-Willi syndrome (PWS). The guidelines are already being implemented at Tennessee’s Prader-Willi Clinic at Monroe Carell Jr. Children’s Hospital at Vanderbilt. The new guidelines were described in the study, “A multidisciplinary approach…

The Foundation for Prader-Willi Research (FPWR) recently announced the first-round winners of its 2019 research awards, which collectively totals a financial investment of $786,000 in grants. Theresa Strong, PhD, the foundation’s director of research programs, described the projects of the eight grant recipients and how their investigations may…

Treatment with an Indian cactus extract reduces appetite in a mouse model of Prader-Willi syndrome (PWS) by interfering with a serotonin receptor in the animal’s brain, a study reports. The study, “Caralluma fimbriata extract activity involves the 5‐HT2c receptor in PWS Snord116 deletion mouse model,” was published in the journal …

Zafgen biopharma and the nonprofit Foundation for Prader-Willi Research (FPWR) have launched “PATH for PWS,” a natural history study aimed at advancing the understanding of the medical history and medical events in patients with Prader-Willi syndrome (PWS). The non-interventional, observational study aims to document serious medical events experienced by Prader-Willi patients…